Daisuke Ennishi
YOU?
Author Swipe
View article: SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma
SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma Open
Background and Significance: Follicular lymphoma (FL) is the most common indolent lymphoma and advanced-stage disease is considered incurable despite recent advances. The current standard initial treatment for patients with FL and high tum…
View article: Comparative Analysis of a Dual <scp>DNA</scp> – <scp>RNA</scp> Panel and a <scp>DNA</scp> ‐Only Panel for Sarcoma: Real‐World Data From a Nationwide Genomic Database
Comparative Analysis of a Dual <span>DNA</span> – <span>RNA</span> Panel and a <span>DNA</span> ‐Only Panel for Sarcoma: Real‐World Data From a Nationwide Genomic Database Open
Next‐generation sequencing‐based comprehensive cancer genomic profiling is promising in cancer management; however, most studies rely on tumor‐only DNA panels from single institutions. In 2023, Japan introduced an insurance‐covered cancer …
View article: Distinct interleukin-6 production in IPL and TAFRO subtypes of idiopathic multicentric Castleman disease
Distinct interleukin-6 production in IPL and TAFRO subtypes of idiopathic multicentric Castleman disease Open
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by systemic inflammation and lymphadenopathy. Two major clinical subtypes, idiopathic plasmacytic lymphadenopathy (iMCD-IPL) and iMCD wit…
View article: Corrigendum to “Genomic landscape and clinical impact of homologous recombination repair gene mutation in small bowel adenocarcinoma” [Eur J Cancer 220 (2025) 115401]
Corrigendum to “Genomic landscape and clinical impact of homologous recombination repair gene mutation in small bowel adenocarcinoma” [Eur J Cancer 220 (2025) 115401] Open
View article: Late‐Onset Invasive Aspergillosis With Pituitary Involvement and Dysfunction Following CD19 Chimeric Antigen Receptor T‐Cell Therapy
Late‐Onset Invasive Aspergillosis With Pituitary Involvement and Dysfunction Following CD19 Chimeric Antigen Receptor T‐Cell Therapy Open
Introduction Invasive fungal infection (IFI) after chimeric antigen receptor (CAR) T‐cell therapy is less common than bacterial and viral infections, but can be fatal once it develops. As most cases occur within 30 days after CAR T‐cell in…
View article: Nationwide Real‐World Usage of Blood‐Based (Liquid) Biomarker Testing in Japan
Nationwide Real‐World Usage of Blood‐Based (Liquid) Biomarker Testing in Japan Open
Despite the advances in precision oncology through biomarker testing, not all patients are able to benefit from treatment decisions guided by tissue‐based testing like comprehensive genomic profiling (CGP). However, the application and int…
View article: Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study Open
Relapsed/refractory (R/R) follicular lymphoma (FL) is a chronic disease often requiring multiple lines of therapy. Covalent Bruton tyrosine kinase inhibitor (BTKi) monotherapy has resulted in variable response rates, yet patients invariabl…
View article: Real‐World Data of Comprehensive Cancer Genomic Profiling Tests Performed in the Routine Clinical Setting in Sarcoma
Real‐World Data of Comprehensive Cancer Genomic Profiling Tests Performed in the Routine Clinical Setting in Sarcoma Open
Introduction Next‐generation sequencing‐based comprehensive cancer genomic profiling (CGP) tests are beneficial for refining diagnosis and personalized treatment of various cancers. However, the clinical impact of CGP, as covered by public…
View article: Cytomegalovirus reactivation in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy
Cytomegalovirus reactivation in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy Open
View article: Distinct age-related effects of homologous recombination deficiency on genomic profiling and treatment efficacy in gastric cancer
Distinct age-related effects of homologous recombination deficiency on genomic profiling and treatment efficacy in gastric cancer Open
Background The incidence of gastric cancer among younger patients is increasing globally, with growing attention being paid to the role of homologous recombination deficiency (HRD). However, the effect of HRD on treatment outcomes and prog…
View article: Genomic heterogeneity and clinical implications in gastrointestinal neuroendocrine carcinoma: MYC and KRAS as predictive biomarkers
Genomic heterogeneity and clinical implications in gastrointestinal neuroendocrine carcinoma: MYC and KRAS as predictive biomarkers Open
Background: Gastrointestinal neuroendocrine carcinoma (GI-NEC) is a highly lethal malignancy with significant clinical and molecular heterogeneities. Given its rarity, large-scale studies are lacking, and research on its genomic landscape …
View article: 290 | REAL‐WORLD SAFETY AND EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: ANALYSIS OF 500 PATIENTS IN THE POLASTAR STUDY
290 | REAL‐WORLD SAFETY AND EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: ANALYSIS OF 500 PATIENTS IN THE POLASTAR STUDY Open
View article: The Involvement of PI3K–Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease–Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified Subtypes
The Involvement of PI3K–Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease–Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified Subtypes Open
Idiopathic multicentric Castleman disease is a rare lymphoproliferative disorder that is clinically classified into idiopathic plasmacytic lymphadenopathy (IPL); thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFR…
View article: Genomic Differences and Distinct <i>TP53</i> Mutation Site‐Linked Chemosensitivity in Early‐ and Late‐Onset Gastric Cancer
Genomic Differences and Distinct <i>TP53</i> Mutation Site‐Linked Chemosensitivity in Early‐ and Late‐Onset Gastric Cancer Open
Background Gastric cancer (GC) in younger patients often exhibits aggressive behavior and a poorer prognosis than that in older patients. Although the clinical differences may stem from oncogenic gene variations, it is unclear whether gene…
View article: A randomized controlled trial of conventional GVHD prophylaxis with or without teprenone for the prevention of severe acute GVHD
A randomized controlled trial of conventional GVHD prophylaxis with or without teprenone for the prevention of severe acute GVHD Open
View article: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial Open
This study received financial support from the Japan Agency for Medical Research and Development, Center for Supporting Hematology-Oncology Studies, and National Cancer Center.
View article: Genomic Landscape and Clinical Impact of Homologous Recombination Repair Gene Mutation in Small Bowel Adenocarcinoma
Genomic Landscape and Clinical Impact of Homologous Recombination Repair Gene Mutation in Small Bowel Adenocarcinoma Open
View article: P143: Original protocol for presumed germline pathogenic variants in cancer genome profiling tests
P143: Original protocol for presumed germline pathogenic variants in cancer genome profiling tests Open
View article: Oral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host disease
Oral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host disease Open
The oral microbiota, second in abundance to the gut, is implicated in chronic systemic diseases, but its specific role in graft-versus-host disease (GVHD) pathogenesis has been unclear. Our study finds that mucositis-induced oral dysbiosis…
View article: Outcomes of allogeneic SCT versus tisagenlecleucel in patients with R/R LBCL and poor prognostic factors
Outcomes of allogeneic SCT versus tisagenlecleucel in patients with R/R LBCL and poor prognostic factors Open
View article: Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma
Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma Open
Primary central nervous system lymphoma (PCNSL) is a rare, aggressive type of lymphoma, most often histologically diagnosed as diffuse large B-cell lymphoma (DLBCL). Recent advancements in single-cell sequencing have elucidated that the di…
View article: Evolving molecular classification of aggressive B‐cell lymphoma
Evolving molecular classification of aggressive B‐cell lymphoma Open
This review aims to provide an overview of the latest developments in the classification and molecular understanding of aggressive B‐cell lymphomas, specifically focusing on diffuse large B‐cell lymphoma (DLBCL) and high‐grade B‐cell lymph…
View article: Axillary Reactive Lymphoid Hyperplasia, Likely Due to Unicentric Castleman Disease, and the Concurrent Presence of Orbital Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: A Six-Year Follow-Up Study
Axillary Reactive Lymphoid Hyperplasia, Likely Due to Unicentric Castleman Disease, and the Concurrent Presence of Orbital Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: A Six-Year Follow-Up Study Open
Castleman disease is a lymphadenopathy of unknown cause at a single site, which is designated as unicentric Castleman disease, or at multiple sites designated as multicentric Castleman disease. We present a patient who showed axillary reac…
View article: Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease
Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease Open
Idiopathic multicentric Castleman disease (iMCD) is a type of Castleman disease unrelated to the Kaposi sarcoma-associated herpesvirus/human herpesvirus type 8 (KSHV/HHV8) infection. Presently, iMCD is classified into iMCD-IPL (idiopathic …
View article: Simulation-based Bone Marrow Aspiration and Trephine Biopsy Education for Medical Students: A Non-randomized Controlled Trial
Simulation-based Bone Marrow Aspiration and Trephine Biopsy Education for Medical Students: A Non-randomized Controlled Trial Open
Objective Despite the critical role of bone marrow aspiration and a trephine biopsy (BMAT) in the diagnosis and management of hematological diseases, research on effective teaching methods is limited. Medical students traditionally learn t…
View article: Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study
Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study Open
This report focuses on part 3 of a multicenter, open-label, phase 1 study (NCT03198650) assessing the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of acalabrutinib plus obinutuzumab in Japanese patients with…
View article: Activated CD4<sup>+</sup> T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy
Activated CD4<sup>+</sup> T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy Open
Objective Chimeric antigen receptor (CAR) T cell therapy is an emerging and effective therapy for relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL). The characteristic toxicities of CAR T cell therapy include cytokine releas…
View article: Recurrent Cerebral Hemorrhaging with Platelet Dysfunction Accompanied by Anti-glycoprotein VI Autoantibodies in a Patient with TAFRO Syndrome
Recurrent Cerebral Hemorrhaging with Platelet Dysfunction Accompanied by Anti-glycoprotein VI Autoantibodies in a Patient with TAFRO Syndrome Open
Thrombocytopenia, anasarca, fever, renal dysfunction, and organomegaly (TAFRO) syndrome is an inflammatory disorder with an unclear pathogenesis. We herein report a case of TAFRO syndrome in remission in a patient who experienced recurrent…
View article: Combination of reduced post‐transplant cyclophosphamide and early tacrolimus initiation increases the incidence of chronic graft‐versus‐host disease in human leukocyte antigen‐haploidentical peripheral blood stem‐cell transplantation
Combination of reduced post‐transplant cyclophosphamide and early tacrolimus initiation increases the incidence of chronic graft‐versus‐host disease in human leukocyte antigen‐haploidentical peripheral blood stem‐cell transplantation Open
We evaluated the clinical impacts of the concurrent modification of post‐transplant cyclophosphamide (PTCy) dose and tacrolimus (Tac)‐initiation timing in 61 patients with human leukocyte antigen‐haploidentical transplantation. Reduced‐dos…
View article: Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study Open